PROLASTIN C LIQUID alpha-1-proteinase inhibitor (human) 1000 mg solution for injection for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

prolastin c liquid alpha-1-proteinase inhibitor (human) 1000 mg solution for injection for intravenous infusion vial

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

PROLASTIN C LIQUID alpha-1-proteinase inhibitor (human) 4000 mg solution for injection for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

prolastin c liquid alpha-1-proteinase inhibitor (human) 4000 mg solution for injection for intravenous infusion vial

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

PROLASTIN C LIQUID alpha-1-proteinase inhibitor (human) 500 mg solution for injection for intravenous infusion vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

prolastin c liquid alpha-1-proteinase inhibitor (human) 500 mg solution for injection for intravenous infusion vial

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

TAKHZYRO lanadelumab 300 mg/2 mL solution for injection pre-filled syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

takhzyro lanadelumab 300 mg/2 ml solution for injection pre-filled syringe

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.

CIPLA IMATINIB ADULT imatinib (as mesilate) 100 mg capsules blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla imatinib adult imatinib (as mesilate) 100 mg capsules blister pack

cipla australia pty ltd - imatinib mesilate, quantity: 119.5 mg (equivalent: imatinib, qty 100 mg) - capsule - excipient ingredients: colloidal anhydrous silica; lactose; magnesium stearate; crospovidone; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

CIPLA IMATINIB ADULT imatinib (as mesilate) 400 mg capsules blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cipla imatinib adult imatinib (as mesilate) 400 mg capsules blister pack

cipla australia pty ltd - imatinib mesilate, quantity: 478 mg (equivalent: imatinib, qty 400 mg) - capsule - excipient ingredients: magnesium stearate; lactose; colloidal anhydrous silica; crospovidone; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

ARYSTA LIFESCIENCE GLYPHOSATE 700 HERBICIDE Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience glyphosate 700 herbicide

arysta lifescience australia pty ltd - glyphosate present as the mono-ammonium salt - water soluble granules - glyphosate present as the mono-ammonium salt glycine active 700.0 g/kg - herbicide - agricultural/farm buildings | almond | annual grass weed - seed set control | avocado | banana | blueberry | buildings - around - african lovegrass | african turnip weed | amaranth or amaranthus | amsinckia | annual phalaris | annual ryegrass | annual weeds | artichoke thistle | australian bluebell - w. gracilis | bamboo | barley grass | barnyard or water grass | bathurst burr | bent grass - agrostis spp. | bitou bush or boneseed | blackberry | bladder ketmia | blady grass | boggabri weed | boxthorn | bracken | brome grass | burr medic | calomba daisy | caltrop or yellow vine | camel or afghan melon | canary grass | capeweed | carpet grass | cat's ear or flatweed | chickweed | chinese scrub | cobbler's pegs | cocksfoot | columbus grass - seedling | couch | cudweed | cumbungi | deadnettle | dock | dock - seedling | english couch or rope twitch | erodium, crowfoot or storksbill | eucalyptus - seedling up to 2 m tall | fumitory | furze or gorse | giant or black pigweed | glyceria or reed sweet grass | gooseberry | ground cherry - physalis angulata | groundsel bush | guinea grass | hawthorn | hedge or wild mustard | hoary cress or whiteweed

ARYSTA LIFESCIENCE BASILICA 300 HERBICIDE Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience basilica 300 herbicide

arysta lifescience australia pty ltd - 2,4-d present as the isopropylamine salt - aqueous concentrate - 2,4-d present as the isopropylamine salt phenoxy acids-2,4-d-amine active 300.0 g/l - herbicide - balansa clover (prior to sowing) | barley | barley - prior to sowing | broom millet | canola (prior to sowing) | cereal rye | ch - amaranth or amaranthus | amsinckia | annual thistle | apple-of-peru | artichoke thistle | australian bindweed - seedling | ball mustard | bathurst burr | bathurst burr - seedling | bellvine - seedling | billygoat weed or blue top | bindweed | bindy-eye | bitou bush or boneseed | blackberry nightshade | blackberry nightshade - seedling | bladder ketmia | blue snakeweed | blue top - ageratum/heliotropium spp. | boxthorn | broadleaf weeds - except noogoora burr | burr medic | californian burr | californian burr seedling | californian thistle | caltrop or yellow vine | caltrop or yellow vine - seedling | camel or afghan melon | canola - brassica napus | cape tulip | capeweed | capeweed - seedling | cat's ear or flatweed | charlock | chinese mint | clockweed | clover | cobbler's pegs | common heliotrope | common iceplant | common storksbill | common vetch or tares | convolvulus vines | cowvine | desiccate broadleaf weeds | dock | dock - seedling | doveweed | fat hen | fleabane | fumitory - red | fumitory - white |